Connect Biopharma's Partner to Present Phase 3 Study Results for Rademikibart in Moderate-to-Severe Atopic Dermatitis at AAD Meeting

Connect Biopharma announced that results from a Phase 3 study of rademikibart in moderate-to-severe atopic dermatitis will be presented at the 2026 American Academy of Dermatology Annual Meeting. The study was conducted by the Company's partner Simcere Pharmaceutical Co., Ltd. in China. The results provide a strong basis for the approval of Simcere's pending New Drug Application for rademikibart in China.